Zoetis Inc. (NYSE:ZTS)‘s stock had its “buy” rating reaffirmed by Stifel Nicolaus in a research note issued on Wednesday. They currently have a $58.00 price objective on the stock. Stifel Nicolaus’ price objective indicates a potential upside of 13.68% from the stock’s current price.

ZTS has been the topic of several other research reports. Bank of America Corp. assumed coverage on Zoetis in a report on Thursday, September 29th. They set a “buy” rating and a $60.00 price objective on the stock. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $53.00 price objective on the stock in a report on Wednesday, June 15th. Citigroup Inc. raised their price objective on Zoetis from $50.00 to $53.00 and gave the company a “neutral” rating in a report on Thursday, August 4th. Credit Suisse Group AG reissued an “outperform” rating and set a $60.00 price objective on shares of Zoetis in a report on Tuesday, August 23rd. Finally, Argus raised their price objective on Zoetis from $54.00 to $58.00 and gave the company a “below average” rating in a report on Friday, September 9th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $55.27.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Shares of Zoetis (NYSE:ZTS) opened at 51.02 on Wednesday. The firm has a 50 day moving average price of $51.26 and a 200 day moving average price of $48.95. The company has a market capitalization of $25.26 billion, a P/E ratio of 39.74 and a beta of 1.01. Zoetis has a one year low of $38.26 and a one year high of $53.14.

Zoetis (NYSE:ZTS) last issued its earnings results on Wednesday, August 3rd. The company reported $0.49 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.05. Zoetis had a return on equity of 77.58% and a net margin of 13.15%. The firm had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter last year, the business posted $0.43 EPS. The company’s revenue was up 2.8% compared to the same quarter last year. On average, equities research analysts predict that Zoetis will post $1.91 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Thursday, November 3rd will be paid a dividend of $0.095 per share. The ex-dividend date of this dividend is Tuesday, November 1st. This represents a $0.38 dividend on an annualized basis and a yield of 0.74%. Zoetis’s dividend payout ratio (DPR) is currently 29.69%.

In other Zoetis news, Director Michael B. Mccallister bought 2,000 shares of the business’s stock in a transaction dated Tuesday, September 6th. The shares were purchased at an average price of $51.34 per share, for a total transaction of $102,680.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Andrew Fenton sold 13,870 shares of the business’s stock in a transaction that occurred on Friday, September 2nd. The stock was sold at an average price of $51.25, for a total value of $710,837.50. Following the completion of the transaction, the insider now owns 17,719 shares in the company, valued at approximately $908,098.75. The disclosure for this sale can be found here. Company insiders own 0.05% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Zoetis by 6.5% in the second quarter. Vanguard Group Inc. now owns 29,819,968 shares of the company’s stock worth $1,415,256,000 after buying an additional 1,812,428 shares during the last quarter. Lazard Asset Management LLC increased its position in shares of Zoetis by 2.7% in the first quarter. Lazard Asset Management LLC now owns 18,464,624 shares of the company’s stock worth $818,534,000 after buying an additional 478,750 shares during the last quarter. Independent Franchise Partners LLP increased its position in shares of Zoetis by 1.7% in the second quarter. Independent Franchise Partners LLP now owns 11,183,747 shares of the company’s stock worth $530,780,000 after buying an additional 188,259 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of Zoetis by 0.9% in the second quarter. Principal Financial Group Inc. now owns 9,890,168 shares of the company’s stock worth $469,388,000 after buying an additional 92,034 shares during the last quarter. Finally, Marshall Wace LLP increased its position in shares of Zoetis by 1.9% in the second quarter. Marshall Wace LLP now owns 9,159,978 shares of the company’s stock worth $434,733,000 after buying an additional 173,902 shares during the last quarter. Hedge funds and other institutional investors own 93.12% of the company’s stock.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

5 Day Chart for NYSE:ZTS

Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.